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Abstract
Background: Prior studies have shown that intermittent fasting is capable of producing improvements in body
weight and fasted health markers. However, the extent to which intermittent fasting incurs compensatory changes
in the components of energy balance and its impact on postprandial metabolism are yet to be ascertained.
Methods: A total of 30–36 lean participants and 30–36 overweight/obese participants will be recruited to provide
two separate study groups who will undergo the same protocol. Following an initial assessment of basic anthropometry
and key health markers, measurements of habitual energy intake (weighed food and fluid intake) and physical activity
energy expenditure (combined heart rate and accelerometry) will be obtained over 4 weeks under conditions of energy
balance. Participants will then be randomly allocated to one of three experimental conditions for 20 days, namely (1) daily
calorie restriction (reduce habitual daily energy intake by 25%), (2) intermittent fasting with calorie restriction (alternate
between 24-hour periods of fasting and feeding to 150% of habitual daily energy intake), (3) intermittent fasting without
calorie restriction (alternate between 24-hour periods of fasting and feeding to 200% of habitual daily energy intake). In
addition to continued monitoring of energy intake and physical activity during the intervention, participants will report
for laboratory-based assessments of various metabolic parameters both before and after the intervention. Specifically,
fasting and postprandial measurements of resting metabolic rate, substrate oxidation, appetite, food preference, and
plasma concentrations of key metabolites and hormones will be made, in addition to subcutaneous abdominal adipose
tissue biopsies in the fasted state and an assessment of body composition via dual-energy x-ray absorptiometry.
Discussion: Comparing observed changes in these measures across the three intervention arms in each group will
establish the impact of intermittent fasting on postprandial metabolism and the components of energy balance in both
lean and overweight/obese populations. Furthermore, this will be benchmarked against current nutritional interventions
for weight management and the relative contributions of negative energy balance and fasting-dependent mechanisms in
inducing any observed effects will be elucidated.
Trial registration: Trial retrospectively registered at clinicaltrials.gov under reference number NCT02498002 (version:
IMF-02, date: July 6, 2015).
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Background
Intermittent fasting (IMF) is a dietary strategy in which
periods of normal food and drink consumption are
punctuated by periods of energy restriction or fasting.
The objective of IMF is to create a net reduction in
energy intake that causes it to fall below energy expend-
iture, thereby creating a state of negative energy balance
and inducing weight loss [1]. Work by various groups
has consistently shown that such an approach is associ-
ated with significant reductions in body mass in obese
participants, whilst also improving blood lipid profile
and lowering concentrations of inflammatory markers
[2–4]. Although these findings are broadly comparable
to those seen following a period of daily calorie restric-
tion [5–13], current understanding of how IMF affects
human health and metabolism is far from complete.
Firstly, while the weight losses reported in prior stud-
ies of IMF reflect a state of negative energy balance, the
precise changes that occur in the components of energy
balance have not been characterised. This is of import-
ance as prolonged periods of daily calorie restriction,
which also aim to create a state of negative energy
balance, elicit compensatory reductions in energy ex-
penditure and increases in appetite that preserve body
fat stores and undermine weight loss efforts [14–22]. Al-
though this adaptive phenomenon has been thoroughly
documented in studies of daily calorie restriction, there
is no evidence to suggest that such a mechanism is
invoked in response to IMF. Changes in leptin concen-
tration, a proposed hormonal regulator of energy
balance [23], have been shown to be similar between
IMF and daily calorie restriction [2, 4, 11, 24]. However,
this does not seem to translate to measurable changes
within the components of energy balance, with studies
failing to detect corresponding reductions in resting
metabolic rate [25] or habitual physical activity [26].
Although promising, these prior studies have focused on
isolated aspects of energy expenditure that do not
accommodate the complex interplay between the com-
ponents of energy balance [1, 21], thus warranting closer
examination.
Secondly, reductions in fasting insulin concentration
have been consistently shown in response to various
IMF interventions as reviewed by Barnosky et al. [8].
This review also highlights that, in a subset of these
studies, fasted indices of insulin resistance generally im-
prove following a period of IMF. However, it is import-
ant to note that these fasted measurements can often
overlook subtle modifications in glucose metabolism
under dynamic conditions [27] such as those seen in the
postprandial period. At present there is a dearth of
knowledge on how IMF impacts postprandial metabol-
ism which needs to be addressed, especially upon
considering that Western cultures spend the majority of
their waking time in a postprandial state [28]. Fur-
thermore, discerning the relative contributions of fast-
ing and negative energy balance to any observed
changes in metabolism carries substantial implications
for how obesity and the associated comorbidities are
treated, as it has been suggested that temporal modi-
fications in energy intake exert independent influences
on metabolic health [29–32].
With over 50% of the adult population in the UK cur-
rently classified as overweight or obese [33], accompan-
ied by an increased risk of type 2 diabetes and
cardiovascular disease, finding more effective strategies
to manage these conditions remains imperative [34].
Although the limited body of prior literature offers
promising insights as to the efficacy of IMF in improving
metabolic health, numerous uncertainties remain. As
such, the present study has three core objectives that
will be separately addressed in both a lean cohort and in
an overweight/obese cohort.
The study will aim (1) to establish whether IMF elicits
compensatory changes in the components of energy bal-
ance and compare these against the changes arising from
a daily calorie restriction intervention; (2) to examine
the effect of IMF on postprandial metabolism relative to
a daily calorie restriction intervention; and (3) to explore
whether IMF impacts upon postprandial metabolism
and the components of energy balance independently




To address these objectives two separate cohorts of 30–
36 healthy adults who satisfy the inclusion/exclusion cri-
teria outlined below will be recruited. One cohort will
feature exclusively lean participants (body mass index
(BMI) 20.5–25.0 kg/m2) and the other overweight/obese
participants (BMI > 25.0 kg/m2). This will be confirmed
using the fat mass index (FMI) obtained from a dual-
energy x-ray absorptiometry (DEXA) scan, with values ≤
7.5 kg/m2 and ≤ 11.0 kg/m2 classified as lean for males
and females, respectively. In line with the objectives of
this protocol the effects of IMF in these two cohorts will
not be compared, instead they will be published as
separate studies with matched methods to provide a
thorough evaluation of the impacts of IMF in these two
metabolically distinct populations.
Participants in each cohort shall then be allocated to
one of three parallel intervention arms in a 1:1:1 alloca-
tion ratio using a stratified randomisation scheme. This
will feature a factor for objectively measured physical
activity level (PAL), which is calculated by dividing each
participant’s total daily energy expenditure by their rest-
ing metabolic rate, to ensure an even distribution of
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lower activity (PAL < 1.75) and higher activity (PAL ≥
1.75) participants in each condition. In accordance with
best practice recommendations for randomised con-
trolled trials [35], allocation concealment will be
employed to minimise bias. The scheme will be gener-
ated by a senior author who is not involved in partici-
pant recruitment or management (JPW) using an
electronic random number generator. Intervention
allocation will be requested via email by those respon-
sible for participant management (IT), with only the
participant code, BMI/FMI and PAL being sent. As only
the delivery team will engage with participants and know
their corresponding code, whilst only the senior author
knows the block sizes and sequences, it is not possible
for the allocation to be reliably predicted or biased by
either party. Full details of the overall randomisation
scheme will be included in publications once all allo-
cations are completed in order to prevent deciphering
[36]. The protocol for these studies has received
ethics approval from the National Health Service
Research Ethics Committee (reference: 15/SW/0007)
and has been registered at clinicaltrials.gov under ref-
erence number NCT02498002 (version: IMF-02, date:
July 6, 2015).
Inclusion
Participants (1) aged 18–65 years, (2) with a BMI of
20.5–25.0 kg/m2 (lean) or > 25.0 kg/m2 (overweight/
obese), (3) a stable body weight (±3 kg) for at least 6
months [37], (4) able and willing to comply with study
procedures, (5) willing to undertake required fasting du-
rations, and (6) with the capacity to provide informed
consent will be included in the study.
Exclusion
Participants (1) with body weight > 120 kg, (2) recent
or planned engagement in fasting practices (within 3
months of start date), (3) recent or planned change in
diet/physical activity habits, (4) suffering from an eat-
ing disorder as assessed using the Eating Disorder
Examination Questionnaire (EDE-Q 6.0) [38], (5)
diagnosed with diabetes or other metabolic health dis-
turbances, (6) with an ongoing medical condition or
treatment that may interfere with study variables, (7)
menopausal, (8) pregnant, recently pregnant, planning
to become pregnant (within 3 months) or currently
breastfeeding, (9) having donated blood within last 3
months, (10) with a lack of capacity/language skills to
independently follow the protocol, (11) who cannot
consume test meals due to intolerances/dietary prefer-
ences (i.e. vegan, gluten, milk proteins), or (12) with
any other behaviour or condition that may introduce
bias to the study or poses undue personal risk, will
be excluded from the study.
Power calculation
The sample size for this study has been estimated using
an a priori power analysis of studies employing similar du-
rations of daily calorie restriction. Specifically, Friedlander
et al. [39] observed a significant decline in resting meta-
bolic rate following 21 days of daily calorie restriction
(pre: 1898 ± 262 kcal/day, post: 1670 ± 203 kcal/day).
Applying a two-tailed t test to these data suggests that 11
participants would be required to achieve 80% power
when detecting such an effect at an alpha level of 0.05. Fo-
cusing instead on changes in postprandial glucose metab-
olism, Molfino et al. [40] reported a significant reduction
in 2-hour post-bolus plasma glucose values during an oral
glucose tolerance test following 10 days of daily calorie
restriction (pre: 10.72 ± 3.56 mmol/L, post: 7.10 ± 2.96
mmol/L). In this instance, nine participants would be re-
quired to detect a comparable within-treatment effect
with 80% power at an alpha level of 0.05. Collectively, this
suggests that 9–11 participants will be required per group
to establish within-treatment effects in the primary out-
comes. However, given the potential for variability in the
outcomes of interest, particularly when working with
obese populations [16, 17], a more conservative require-
ment of 10–12 was decided upon. With 10–12 partici-
pants required in each of the three intervention arms,
30–36 lean participants and 30–36 overweight/obese
participants will be sought in total, allowing examination
of these two metabolically distinct populations to be kept
separate. Recruitment will be conducted using adverts at
local employers and media outlets, and will proceed on a
rolling basis until an adequate sample size is reached. To
minimise loss to follow-up emphasis will be placed on
considering the demands of the study before enrolling and
that feedback of personal results will only be available to
those who complete all three lab sessions. In cases of with-
drawal, additional participants will be sought to maintain
statistical power; however, the point of withdrawal and the
accompanying reason will be reported in a CONSORT
flow diagram in subsequent publications.
Experimental protocol
Overview
Having read the participant information sheet (Additional
file 1) and discussed the study in its entirety with a mem-
ber of the research team (IT), potential participants will be
guided through the process for providing written informed
consent (Additional file 2). Following this, eligibility will be
assessed by a series of self-report questionnaires together
with a BMI calculation. Eligible participants will then
undergo the 8-week protocol shown in Fig. 1a. All lab
sessions will be completed at the University of Bath
(Somerset, UK) whilst all other aspects of the study will
occur under free-living conditions. In preparation for all la-
boratory sessions, participants will avoid caffeine, alcohol,
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smoking and strenuous exercise throughout the preceding
24 hours, whilst also standardising their dietary intake.
Following an overnight fast (minimum 10 hours) partici-
pants will report to the laboratory at 07:30 ± 01:00 having
consumed 500 mL of water upon waking. Female partici-
pants will schedule all laboratory sessions to coincide with
the follicular phase of their menstrual cycle (i.e. 3–10 days
after onset of menses) to account for monthly fluctuations
in hormone levels and the associated changes. A SPIRIT
figure showing the schedule of enrolment, assessment of
outcome measures, allocation and interventions across the
8-week timeline is shown in Fig. 2, and the accompanying
SPIRIT checklist can be found in Additional file 3.
LAB 1 (baseline)
This initial lab session will provide a reference point for
examining the stability of body mass, as an indicator of
overall energy balance, throughout the ensuing 4-week
monitoring phase in which habitual dietary intake and
physical activity are quantified. In addition, this visit will
serve to familiarise participants with key procedures to
improve reliability over subsequent laboratory sessions
[41, 42]. Specifically, this will involve the provision of a
urine sample to measure hydration status before both
height and body mass are measured. Resting metabolic
rate and substrate oxidation will be quantified using indir-
ect calorimetry of expired air samples, after which a fasted
blood sample shall be drawn from the antecubital vein to
measure baseline concentrations of certain biomarkers
(e.g. glucose, cholesterol). To conclude this session, a su-
pervised submaximal treadmill protocol will also be
undertaken to individually calibrate the physical activity
monitors being used throughout the study (Actiheart™).
Monitoring phase
During this 4-week phase, participants will be asked to
maintain their habitual diet and activity patterns. Within
this, both energy intake and physical activity will be
measured concurrently in four designated monitoring
windows of 3 consecutive days each. These windows will
be separated by at least 2 days and the final window will
coincide with the 3 days leading up to LAB 2. Data on
physical activity energy expenditure and intensity will be
captured using individually calibrated ActiheartTM moni-
tors [43, 44], whilst energy intake will be measured by
means of a weighed record of food and fluid intake. To
proceed into the next phase, participants will be re-
quired to maintain energy balance throughout the
monitoring phase and provide accompanying mea-
surements of energy intake and expenditure. Energy
balance will be ascertained by maintaining a stable
body weight (<1.0 kg increase or decrease) between
LAB 1 and LAB 2 [16, 45].
LAB 2 (pre-intervention)
Having completed the monitoring phase, participants
will then return to the laboratory for measurement of a
series of fasted and postprandial outcomes. Once again,
hydration status will be ascertained from a urine sample
before body mass is measured. As discussed previously,
if body mass differs from the value recorded in LAB 1
by more than 1.0 kg then participants will be asked to
repeat the monitoring phase. Providing this criterion is
satisfied, then fasting measurements of resting metabolic
rate and substrate oxidation will be repeated before a
cannula is fitted to an antecubital vein and a fasting ven-
ous blood sample is drawn. In order to examine changes
at the tissue level, a subcutaneous adipose tissue biopsy
will also be obtained from the abdominal region at this
time. The last of these fasted measurements will be a set
a visual analogue scales and computer-based tasks to as-
sess perceived hunger, fullness, desire to eat and food
preferences. This will then be followed by two sequential
test meals. The first will feature indirect calorimetry
Fig. 1 Schematic of the 8-week study design (a) and the sampling intervals for laboratory sessions 2 and 3 (b). DEXA dual-energy x-ray absorptiometry
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measurements from expired gases, visual analogue
scales/computer tasks, and venous blood samples,
whereas the second will only involve sampling of arteria-
lised venous blood. Figure 1b shows the sampling
intervals for the various measurements. Blood samples
will be used to examine both postprandial nutrient
handling (e.g. glucose, insulin, triglyceride concentra-
tions) and appetite regulation (e.g. ghrelin, peptide YY
concentrations). To conclude, a DEXA scan will be per-
formed to measure pre-intervention fat and lean tissue
mass.
Intervention phase
During a 6-day rest following LAB 2, which is included
to avoid prolonged periods of monitoring [46] and main-
tain the 4-week testing interval, participants will be
Fig. 2 SPIRIT 2013 figure showing schedule of enrolment, assessments, allocation and intervention for each participant. NEFA non-esterified fatty
acids, PYY peptide YY, DEXA dual-energy x-ray absorptiometry
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randomised to one of the three parallel intervention
arms outlined in Table 1. The three diet groups will last
for 20 days each with transitions between 24-hour cycles
occurring at 15:00 each day. Not only does this transi-
tion point allow the consumption of at least one main
meal per day to aid motivation, but more importantly, it
also ensures that the latter and more demanding part of
the fast coincides with diurnal reductions in appetite to
encourage adherence [47]. Furthermore, this structure
still gives a full 24-hour fasting period, which is around
double that achieved in most prior studies [8].
For the IMF groups, during fasted cycles, participants
are only permitted water, herbal teas and black tea/cof-
fee with no sugar (i.e. unsweetened energy-free drinks).
During feeding cycles, and throughout the daily calorie
restriction diet, participants will appropriately modify
their normal diet to give 75%, 150% or 200% of their ha-
bitual daily energy intake (measured during monitoring
phase) in accordance with the group they are assigned
to. Participants will also continue to monitor their phys-
ical activity and energy intake over the first and last 6
days of the intervention period. In the context of phys-
ical activity, this is to examine behavioural adaptations
to the different diets; therefore, participants are allowed
to adjust the quantity of activity/exercise undertaken
based on how they feel, but are instructed not to incorp-
orate any unfamiliar activities. In contrast, measure-
ments of energy intake will be used to monitor
compliance with intake targets with feedback provided
to maximise accuracy. It is anticipated that, for some
participants, doubling the volume of their habitual diet
to achieve the calorie target whilst maintaining macro-
nutrient balance will not be feasible. In these circum-
stances, achieving the required calorie intake will take
precedence over maintaining macronutrient balance,
both of which will be reported in resulting publications.
LAB 3 (post-intervention)
Following the completion of 20 consecutive 24-hour
dietary cycles, participants will be required to standard-
ise their diet and activity levels for 1 day to match those
reported in the lead up to previous lab sessions and
eliminate any residual effects of the final diet period. As
with LAB 1 and LAB 2, this will also involve avoiding
caffeine, alcohol, smoking and strenuous exercise before
completing an overnight fast (minimum 10 hours) and
consuming 500 mL of water upon waking. At 07:30 ±
01:00, participants will return to the laboratory and
repeat the protocol outlined earlier for LAB 2, thereby
providing a pre–post comparison.
Anthropometry
Having voided upon arrival, measurements of body mass
will be taken to the nearest 0.05 kg (Weylux 424, UK)
with participants wearing light clothing. Height will be
measured using a wall-mounted stadiometer to the near-
est 0.1 cm whilst participants stand with their heels and
shoulders touching the stadiometer. Body composition
will be assessed by means of a DEXA scan (Discovery
W, Hologic, MA, USA) taken in a supine position. For
this, participants will be asked to lie on the scanning
table with their feet evenly spaced to either side of the
midline. Arms will be placed by their sides and equidis-
tant to the trunk with the hands pronated and fingers
spread. All measurements will be made following a qual-
ity control scan of a spine phantom with known proper-
ties in accordance with the manufacturer’s instructions.
Energy intake
Energy intake will be measured throughout both the
monitoring and intervention phases by means of a
weighed record of food and fluid intake. In the initial lab
session, participants shall be provided with a set of com-
pact kitchen scales (SmartWeighTM Pocket Pro, NY,
USA) and a log book to record all food and drink items.
In addition, a researcher will discuss best practice with
them and emphasise the level of detail required. These
weighed records will be analysed (NutriticsTM, Ireland)
to yield values for energy and macronutrient intake with
all records for a given participant analysed by the same
researcher.
Physical activity
Physical activity will be measured using Actiheart™ mon-
itors (CamNtech, UK) that employ combined heart rate
and accelerometry data to yield minute-by-minute esti-
mates of physical activity energy expenditure and inten-
sity under free-living conditions [43]. These monitors
will be individually calibrated for each participant using
an adapted version of the treadmill protocol described
by Brage et al. [44]. Specifically, this involves completing
four 3-minute stages of supervised incremental treadmill
locomotion, namely level walking at 3.2 km/h, brisk level
walking at 5.2 km/h, brisk graded walking at 5.8 km/h
(+10%) and level running at a self-selected speed of 9.0–
12.0 km/h. During the final minute of each stage, heart
rate (RS400, Polar, Finland) and energy expenditure (in-
direct calorimetry of expired air samples) will be
Table 1 Intervention arms employed in the study protocol
Intervention Description
Daily calorie restriction Reduce normal intake by 25% every day
Intermittent fasting with
calorie restriction
Alternate between 24-hour periods of
fasting and feeding with 150% of
normal intake on fed days
Intermittent fasting
without calorie restriction
Alternate between 24-hour periods of
fasting and feeding with 200% of
normal intake on fed days
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measured. This will yield a heart rate–physical activity in-
tensity regression equation for each participant which ac-
commodates the inter-individual differences in this
relationship to dramatically improve concurrent validity
[44]. However, participants can choose to omit the final
stage (level running) if they do not feel able in order to
avoid biasing the sample in favour of more formal exer-
cisers. Furthermore, the treadmill protocol will also be
ended prematurely if the participant asks to stop or if their
heart rate exceeds 85% of their age-predicted maximum.
Meal tests
In order to examine the impact of the interventions on nu-
trient handling and appetite regulation, in addition to any
second meal effects [48], two successive meal tests will be
completed in LAB 2 and LAB 3. Both meals will be tailored
to provide one-third of resting metabolic rate as measured
in the fasted state during LAB 2. The first meal (breakfast)
will be in the form of a homogenous porridge meal (1.31
kcal/g; 59% carbohydrate, 29% fat, 12% protein) composed
of golden syrup flavour instant oats (Sainsbury’s, UK),
whole milk (Tesco, UK) and white granulated sugar (Silver
Spoon, UK). This will be cooked in a microwave and cooled
for 10 minutes before being consumed in its entirety within
a designated 10-minute eating opportunity. This will be
followed by a 3-hour postprandial period featuring venous
blood samples (15, 30, 45, 60, 90, 120, 180 minutes), visual
analogue scales (30, 60, 90, 120, 150, 180 minutes),
computer-based food-choice tasks (45, 105, 165 minutes)
and expired air samples (60, 120, 180 minutes).
By comparison, the second meal (lunch) will take the
form of a liquid meal-replacement supplement (1.50
kcal/mL; 54% carbohydrate, 30% fat, 16% protein; Ensure
Plus, Abbott Nutrition, OH, USA) which will be
consumed following a blood sample within a 5-minute
feeding window positioned 210 minutes after the con-
sumption of the first meal. A 2-hour postprandial period
will then follow in which arterialised venous blood sam-
ples will be drawn using the heated hand-box method
(225, 240, 255, 270, 300, 330 minutes).
Indirect calorimetry
Resting metabolic rate and substrate oxidation in both the
fasted and postprandial state will be measured using indir-
ect calorimetry of expired air samples [49]. In each in-
stance, three consecutive 5-minute air samples will be
collected using a mouthpiece and the Douglas bag method
(Hans Rudolph, MO, USA) before analysis (Servoflex
MiniHF 5200, Servomex, UK) and evacuation (Dry Gas
Meter, Harvard Apparatus, MA, USA). Samples will be
collected in accordance with best practice guidelines [50],
with the values from two or more samples that agree to
within 100 kcal/day averaged and used in further analysis
[37], along with the corresponding substrate oxidation
parameters. During the treadmill test for the calibration of
activity monitors, a single 1-minute air sample will be col-
lected per stage for which a facemask shall be used in
place of the mouthpiece for participant comfort.
Blood sampling
In LAB 2 and LAB 3, all blood samples will be procured
by means of an intravenous cannula. At each sampling
interval, the first 2 mL of the draw will be discarded as
waste before a 5 mL sample is collected. This sample
will then be dispensed in to an EDTA tube and centri-
fuged before the supernatant is aliquoted across three
1.5 mL tubes and stored at −80 °C pending subsequent
analysis for plasma concentrations of nutrients (e.g.
glucose, triglycerides) and regulatory hormones (e.g. insu-
lin, leptin). In the fasted state, and at hourly intervals in
each postprandial period, an additional 5 mL will also be
drawn to quantify plasma concentrations of hormones im-
plicated in appetite regulation (e.g. ghrelin, peptide YY).
Once obtained, this additional 5 mL will be immediately
transferred to an EDTA tube to which 50 μL of a 1.0 mM
p-hydroxymercuribenzoic (PHMB) acid solution has been
added. This will then also be centrifuged before 600 μL of
the supernatant is removed and transferred to a sterile
tube containing 60 μL of 1 M hydrochloric acid and cen-
trifuged once again. The PHMB and acidified plasma sam-
ples will then be aliquoted into two separate 1.5 mL tubes
and stored at −80 °C for later analysis. Following the draw
of each blood sample, the cannula will be flushed with a
0.9% sodium chloride solution to keep it patent. All sam-
ples will be centrifuged (Biofuge Primo R, Heraeus,
Germany) at 4 °C for 10 minutes at 3466×g.
Adipose tissue biopsy
Adipose tissue biopsies will be obtained from the sub-
cutaneous abdominal region. For this, a site 5 cm to the
left or right of the umbilicus will be sterilised and anaes-
thetised (1% lidocaine hydrochloride without adrenaline,
Hameln Pharmaceuticals, UK) before a sample is ob-
tained using the needle aspiration method [51]. This
sample will be cleaned on 100 nm gauze with a sterile
0.9% sodium chloride solution before being separated
into aliquots of approximately 250 mg. One aliquot will
be immediately disrupted in TRIzol (Invitrogen) using a
hand-held homogeniser (Fisher Scientific, CA, USA) and
frozen at −80 °C for subsequent analysis. The second ali-
quot will be immediately frozen at −80 °C. Biopsies ob-
tained in LAB 2 and LAB 3 will be taken from opposing
sides of the umbilicus.
Urine collection
Urine samples will be collected at the outset of each lab
session to ensure participants are similarly hydrated for
repeated body mass measurements. The samples will be
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analysed on the day for osmolality, via the freeze-point
depression method (Micro Osmometer 3300, Advanced
Instruments, MA, USA) and specific gravity (SUR-NE
Clinical, Atago, Tokyo). Furthermore, during the 3-hour
postprandial period which follows the breakfast meals,
total urine output will be collected into containers pre-
pared with 5 mL of a 10% thymol–isopropanol solution.
At the end of the 3-hour period, the total volume of
urine will be measured with a 1 mL sample extracted
and frozen at −80 °C for subsequent analysis of urine
urea concentration, as an indicator of protein excretion,
to calculate the contribution of protein oxidation to
whole body energy metabolism.
Appetite
Appetite will be measured using visual analogue scales
[52] assessing hunger, stomach fullness, desire to eat,
thirst and food preference (sweet, salty, savoury, fatty),
and two computer-based tasks. For each of the visual
analogue scales there will be a question (e.g. how hungry
do you feel?) followed by a 100 mm visual scale with the
extremes defined (e.g. not at all – as hungry as I have
ever felt). Participants shall be asked to place a vertical
line on the scale to denote their perception relative to
the two extremes, with the distance from the zero point
to the marked point measured and recorded by the same
researcher for all scales.
The computer-based tasks are a two alternative forced
choice task (2AFCT) and an ideal portion size task
(IPST) [53]. The 2AFCT comprises a set of 18 foods
which are individually photographed in an approxi-
mately standard portion on a white plate, or in a plain
glass bowl placed on the white plate. In terms of nutri-
ent composition and taste, there are six triplets of foods.
The foods within each triplet have a very similar energy
density and weight, and across the triplets energy density
varies from 1.1 kcal/g to 5.0 kcal/g. Each triplet contains
one sweet high-carbohydrate food, one non-sweet high-
carbohydrate food and one non-sweet low-carbohydrate
food. An example triplet is vanilla ice cream, Singapore
noodles and stir-fry sauce, and tuna and mayonnaise. In
the task, each food is paired side-by-side once with all of
the other foods to give a total of 153 trials (the side on
which the foods appears is randomised across trials). For
each pair of foods, the participant indicates by depress-
ing the left or right arrow-key on the computer keyboard
which food they would ‘choose to eat right now’. Out-
come measures are (1) proportion of trials on which a
high-sweetness, high-carbohydrate food is chosen, (2)
proportion of trials on which a low-sweetness, high-
carbohydrate food is chosen, (3) proportion of trials on
which a low-carbohydrate food is chosen, and (4) aver-
age energy content of the chosen foods for each of these
categories. There is a ‘base rate’ for each category
because, on some occasions, there will be a choice be-
tween two low-carbohydrate foods, for example, but
these will differ in energy content/density. For the IPST
[54], there are three test foods, vanilla ice cream,
Singapore noodles and stir-fry sauce, and tuna and may-
onnaise, which are photographed in portions ranging
from 20 to 1000 kcal in 20 kcal increments (50 pictures
in total). In each of three trials one of these foods is dis-
played in the middle of the computer screen. Depressing
the left arrow-key causes the portion size to decrease (a
smaller portion is displayed) whilst pressing the right
arrow-key causes the converse. The pictures are loaded
with sufficient speed that continuous depression of the
left or right arrow key gives the appearance that the
change in portion size is animated. Each trial starts with
a different and randomly selected portion size. Partici-
pants are instructed to ‘Imagine you are offered this food
right now. Use the left and right arrow keys to adjust the
portion to show how much of it you would eat.’
These measures are designed to complement measures
of hormones implicated in appetite control and account
for any changes in how satiety signals are interpreted.
Furthermore, the two computer tasks will determine
whether the different interventions influence preference
for sweet or non-sweet carbohydrates, or both. The vis-
ual analogue scales shall be completed in the fasted state
and at 30 minute intervals following the breakfast meal
in LAB 2 and LAB 3. The computer-based tasks will be
completed in a fasted state and 45, 105 and 165 minutes
after the breakfast meal.
Data management
Upon providing informed consent, participants will be
assigned with a unique identifier that will be used on all
data collection documentation to preserve confidential-
ity. Data recorded in physical form will be digitised and
stored in a central file that can only be accessed by the
research team. Once a complete dataset has been com-
piled, manuscripts will be drafted and submitted for
publication in appropriate peer-reviewed journals. The
criteria that warrant an authorship in resulting publica-
tions will be addressed once data analysis has been com-
pleted. Once the results have been formally published
the trial dataset will be released in anonymised form and
an engagement event will be arranged to inform partici-
pants of the findings. Should any data or biological
samples collected in the present study be needed for an-
cillary studies, appropriate consent will be sought from
participants before proceeding.
A full risk assessment has been conducted by the re-
search team and was subsequently approved by the re-
search sponsor and the NHS Research Ethics Committee
(Frenchay). Prior to enrolling, all participants will be
fully informed of the potential risks associated with
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engaging in this study. In particular this will centre upon
the symptoms they may experience as a result of prolonged
fasting and dietary restriction (e.g. headaches, tiredness,
hunger, irritability, spells of dizziness/faintness), as well as
the risk of discomfort and infection that accompanies tissue
biopsy and blood sampling procedures. Participants will be
free to withdraw from the study at any time during their in-
volvement. As neither participants nor researchers are
blinded to trial allocation the research team will take re-
sponsibility for noting and reporting adverse events to the
study sponsor and the ethics committee. Overall conduct
of the trial, including adverse event reporting, data manage-
ment protocols and researcher conduct, will be subject to
biannual progress reports by the research sponsor.
However, there is no intention to end the trial prematurely
based in interim results which, together with the wider data
monitoring framework, renders a data monitoring commit-
tee unnecessary. Any modifications to the study protocol
will be submitted to the trial sponsor and NHS research
ethics committee (Frenchay); if approved, publications and
trial registrations will be updated accordingly.
Data analysis
As outlined in the aims of the present study, the primary
outcomes will explore the effects of the intervention on
postprandial glucose/insulin responses (pre–post) and
energy balance – reflected by changes in resting
metabolic rate (pre–post), physical activity energy ex-
penditure (monitoring–intervention) and postprandial
thermogenesis (pre–post). Secondary outcomes will
explore changes from pre- to post-intervention in body
composition, substrate oxidation, lipid profile, leptin
concentration, c-reactive protein concentration, adipose
tissue gene expression, postprandial lipaemia and post-
prandial appetite regulation/perception. In addition,
differences in physical activity intensity and dietary com-
position between the monitoring and intervention
phases will be examined. As it is not the objective of this
study to compare these differences between the cohorts,
two sets of analyses will be conducted on a per protocol
basis -– one for the lean cohort and one for the over-
weight/obese cohort. Both will centre upon a two-way
mixed model analysis of variance featuring a factor for
diet allocation and a factor for time-point. This will
permit an examination of the effect of each diet on the
outcomes of interest (i.e. pre vs. post/monitoring vs.
intervention) and whether this effect varied between the
three dietary conditions. Pre-existing differences
between groups at baseline will be examined using a
one-way analysis of variance featuring a factor for diet
allocation. Significant differences emerging from these
tests will be explored using appropriate post-hoc tests to
adjust for multiple comparisons and isolate the source(s)
of variance. In addition to these analyses at the group
level, individual responses will also be closely scrutinised
to examine whether outliers could be affecting the inter-
pretation. Further analysis, such as sub-group analysis,
may also be conducted in light of patterns emerging in
the final dataset. Baseline characteristics of participants
who withdraw during the intervention will also be com-
pared against the final population using t tests. Statistical
significance will be accepted at P < 0.05.
Discussion
Despite the growing popularity of IMF [55], research ex-
ploring its effects on human metabolism remains scarce.
The novel examination of postprandial responses and
the components of energy balance being employed in
this study will highlight the extent to which IMF regimes
can impact human metabolism. The isocaloric contrast
of IMF and daily calorie restriction will also add a
further dimension by thoroughly benchmarking IMF
against current nutritional strategies for improving
metabolic health. Furthermore, the inclusion of a eucalo-
ric IMF arm will examine whether any observed changes
can be attributed to extended fasting alone as opposed
to chronic energy imbalance. Finally, in exploring all of
these facets in both lean and overweight/obese groups,
the present study will also clarify the effect of baseline
adiposity on observed changes, which may unravel the
discrepancies seen in prior studies [56, 57]. Taken
together, this approach will help to provide clearer and
more informed public health messages on the safety
and efficacy of such diets relative to conventional
approaches.
Trial status
This trial was retrospectively registered on July 6, 2015,
at clinicaltrials.gov under identifier NCT02498002
(version: IMF-02). Recruitment commenced on June 8,
2015, and is currently ongoing. It is anticipated that
recruitment will be completed by July 2018.
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